According to the current European Guidelines on the management of HF [1], an array of disease-modifying drugs including beta-blockers, ACEI, ARNI, MRA, ivabradine and sodium–glucose cotransporter-2 (SGLT2) inhibitors, are recommended in patients with HFrEF in the light of strong scientific evidence from landmark randomized controlled trials. Here, SLC5A2 is linked to hydrops fetalis.